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Abstract
Background. Several studies with erythropoiesis-stimulat-
ing agents claim that maintenance therapy of renal anaemia
may be possible at extended dosing intervals; however,
few studies were randomized, results varied, and compar-
isons between agents were absent. We report results of a
multi-national, randomized, prospective trial comparing
haemoglobin maintenance with methoxy polyethylene
glycol-epoetin beta and darbepoetin alfa administered
once monthly.
Methods. Haemodialysis patients (n = 490) on stable once-
weekly intravenous darbepoetin alfa were randomized to
methoxy polyethylene glycol-epoetin beta once monthly
or darbepoetin alfa every 2 weeks for 26 weeks, with dose
adjustment for individual haemoglobin target (11–13 g/dL;
maximum decrease from baseline 1 g/dL). Subsequently,
patients entered a second 26-week period of once-monthly
methoxy polyethylene glycol-epoetin beta and darbepoetin
alfa. The primary endpoint was the proportion of patients
who maintained average haemoglobin ≥10.5 g/dL, with a
decrease from baseline ≤1 g/dL, in Weeks 50–53; the sec-
ondary endpoint was dose change over time. The trial is re-
gisteredatwww.ClinicalTrials.gov,numberNCT00394953.
Results. Baseline characteristics were similar between
groups. One hundred and fifty-seven of 245 patients trea-
ted with methoxy polyethylene glycol-epoetin beta and 99
of 245 patients with darbepoetin alfa met the response def-
inition (64.1% and 40.4%; P<0.0001). Doses increased by
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Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa 40096.8% with methoxy polyethylene glycol-epoetin beta and
58.8% with darbepoetin alfa during once-monthly treat-
ment. Death rates were equal between treatments (5.7%).
Most common adverse events included hypertension, pro-
cedural hypotension, nasopharyngitis and muscle spasms,
with no differences between groups.
Conclusions. Methoxy polyethylene glycol-epoetin beta
maintained target haemoglobin more successfully than dar-
bepoetin alfa at once-monthly dosing intervals despite
dose increases with darbepoetin alfa.
Keywords: anaemia; chronic kidney disease; darbepoetin alfa;
erythropoiesis-stimulating agent; methoxy polyethylene glycol-epoetin
beta
Introduction
Anaemia is a common complication of chronic kidney
disease, and correction of anaemia with erythropoiesis-
stimulating agents is associated with improved patient out-
come [1] and quality of life [2].
Approved erythropoiesis-stimulating agents with short
half-lives generally require short dosing intervals and fre-
quent administration (mainly two to three times per week)
to maintain stable haemoglobin concentrations [3]. An
erythropoiesis-stimulating agent with a longer half-life
and correspondingly longer dose interval might improve
anaemia management and provide greater convenience to
patients [4] while decreasing the impact on health-care re-
sources, especially given the increasing incidence and
prevalence of chronic kidney disease [5]. This has led to
clinical testing of available erythropoiesis-stimulating
agents at dosing intervals longer than those in approved
labelling. However, most published studies tested dosing
intervals shorter than once monthly and used uncontrolled
designs [6,7].
Methoxy polyethylene glycol-epoetin beta, a continuous
erythropoietin receptor activator (C.E.R.A.), is approved
without restrictions for once-monthly maintenance therapy
for anaemia in patients with chronic kidney disease, while
once-monthlyadministrationofdarbepoetinalfaisapproved
in Switzerland [8] but restricted to pre-dialysis patients
stable at the 2-week dosing interval in the EU [9]. The aim
of the PATRONUS (comPArator sTudy of C.E.R.A. and
darbepOetin alfa in patieNts Undergoing dialySis) study
was to compare the efficacy and safety of methoxy poly-
ethylene glycol-epoetin beta and darbepoetin alfa, each ul-
timately administered intravenously once monthly for the
maintenance of haemoglobin concentrations in dialysis pa-
tients, in a prospective, parallel-group design.
Materials and methods
Study participants
Patients were screened from 82 centres in Europe, Canada and Australia
and were aged ≥18 years, had stable chronic renal anaemia (with a
haemoglobin range of 11–13 g/dL) and were on regular haemodialysis
(Figure 1). To be included in the study, patients must have received
haemodialysis three times weekly for ≥12 weeks before screening and
during the 4-week screening/baseline period. Eligible patients must have
had stable haemoglobin concentrations, defined as a maximum variation
of 1 g/dL during the screening/baseline period. They must have under-
gone continuous once-weekly maintenance intravenous darbepoetin alfa
therapy for ≥8 weeks before screening and during the screening/baseline
period. Patients were not selected on the basis of darbepoetin alfa dose.
Only one dose change was allowed during the screening/baseline period.
Patients also had to have adequate iron status, defined as serum ferritin
≥100 µg/L, transferrin saturation ≥20% or <10% hypochromic red blood
cells. Patients were excluded from the study if they had overt bleeding that
necessitated red blood cell transfusion within 8 weeks of the start of
screening or during the screening/baseline period; a non-renal cause of
anaemia; C-reactive protein >30 mg/L; the likelihood of early withdrawal;
or life expectancy of <12 months.
This open-label, randomized, multicentre, parallel-group phase III
study was designed in accordance with the Declaration of Helsinki and
the Guidelines for Good Clinical Practice of the International Conference
on Harmonisation. The design was approved by the review boards or eth-
ics committees of participating institutions. All participants gave prior
written informed consent.
Procedures
Figure 2 shows the treatment protocol. All patients entered a 4-week
screening/baseline period during which they continued to receive their
previous darbepoetin alfa treatment (Amgen, Thousand Oaks, CA,
USA). Eligible patients were then randomly assigned (1:1) to receive
intravenous methoxy polyethylene glycol-epoetin beta (F. Hoffmann-La
Roche, Basel, Switzerland) once monthly or darbepoetin alfa every
2 weeks for a first 26-week treatment period. Patients were randomized
between December 2006 and November 2007.
The starting dose of methoxy polyethylene glycol-epoetin beta was
based on the previous weekly dose of darbepoetin alfa in the week before
randomization.For patientswhopreviouslyreceived<40µgofdarbepoetin
alfa per week, the starting dose of methoxy polyethylene glycol-epoetin
beta was 120 µg. Patients who had received 40–80 µg or >80 µg of darbe-
poetin alfa per week were given 200 or 360 µg of methoxy polyethylene
glycol-epoetin beta, respectively. The starting dose of darbepoetin alfa
every 2 weeks was twice the weekly dose of darbepoetin alfa in the week
before randomization.
After an initial 26-week period, patients entered a second 26-week
treatment period, during which both study medications were administered
once monthly: the first once-monthly dose of darbepoetin alfa was double
the last dose of the first 26-week treatment period, while methoxy poly-
ethylene glycol-epoetin beta was continued at the same dose and interval
as in the first 26-week period.
Doses for all patients were to be adjusted so that haemoglobin concen-
trations would remain within a target range of 11–13 g/dL and not de-
crease >1 g/dL compared with each individual patient’s baseline. Doses
of methoxy polyethylene glycol-epoetin beta were to be adjusted accord-
ing to protocol and not more often than once monthly. Doses of methoxy
polyethylene glycol-epoetin beta were to be decreased by 25% for haemo-
globin >13 and ≤14 g/dL and increased by 25% for haemoglobin de-
creases >1 g/dL versus baseline or for haemoglobin <11 and ≥9 g/dL.
Methoxy polyethylene glycol-epoetin beta dose decreases of 50% were
to be made for haemoglobin increases >2 g/dL versus baseline and in-
creases of 50% for haemoglobin decreases >2 g/dL versus baseline or
haemoglobin <9 g/dL. Treatment was to be interrupted temporarily if
haemoglobin exceeded 14 g/dL.
Darbepoetin alfa doses were to be adjusted according to the approved
prescribing information, without additional restrictions.
Iron supplementation was to be initiated or intensified according to
centre practice in cases of iron deficiency (serum ferritin <100 µg/L,
transferrin saturation <20%, or hypochromic red blood cells >10%) and
discontinued in patients who had serum ferritin levels >800 µg/L or trans-
ferrin saturation >50%.
Randomization and masking
Randomization numbers were generated by computer at a coordinating
centre and allocated to the two treatment groups in a 1:1 ratio using a
permuted block randomization with a block size of four, in the order in
which patients were enrolled. Randomization was not stratified by centre;
therefore, identification of the next patient in the sequence was impos-
4010 F. Carrera et al.sible. Investigators received numbers by telephone and recorded them on
patients’ electronic case-report forms. This was an open-label study;
therefore, the treatment assignment was not masked.
Study outcomes
The primary efficacy endpoint was the proportion of responders on once-
monthly treatment in the second treatment period in the intent-to-treat
population, i.e. all randomized patients with a haemoglobin decrease from
baseline ≤1 g/dL and an average haemoglobin ≥10.5 g/dL during the
evaluation period (Weeks 50–53).
The secondary efficacy endpoint was the difference between the
monthly dose in Week 27 and the average dose in months 11 and 12 for
the two study groups.
Assessments
Patients were assessed every week during the screening/baseline period,
the 52-week treatment period and at the final visit. At each assessment,
all patients who had received at least one dose of study drug throughout
the treatment protocol were asked whether they had experienced any
adverse events. Blood pressure, heart rate, haemoglobin and haematocrit
703 screened
490 randomised
First
26-week
treatment 
period
245 allocated to methoxy polyethylene
glycol-epoetin beta once monthly
245 allocated to darbepoetin alfa 
every 2 weeks
Second
26-week
treatment 
period
216 participated (once monthly) 222 participated (once monthly)
187 completed study 148 completed study
245 follow-up population 244 follow-up population
213 excluded
     1 red blood cell transfusion
     1 non-renal anaemia
     16 C-reactive protein
     5 likely to withdraw
     2 life expectancy <12 months
     188 other
29 withdrew
     1 adverse event
     6 deaths
     1 insufficient response
     6 refused treatment
     11 renal transplants
     4 other
23 withdrew
     2 adverse events
     7 deaths
     1 insufficient response
     3 refused treatment
     7 renal transplants
     1 failure to return
     2 other
29 withdrew
     2 adverse events
     8 deaths
     9 insufficient response
     3 refused treatment
     4 renal transplants
     3 other
74 withdrew
     5 adverse events
     4 deaths
     47 insufficient response
     3 refused treatment
     6 renal transplants
     1 failure to return
     8 other
Fig. 1. Screening and enrolment of study patients.
Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa 4011were measured at every visit. White blood cell count, platelet count,
aspartate amino transferase, alanine aminotransferase, albumin, alkaline
phosphatase, C-reactive protein, potassium, phosphorus, serum ferritin,
serum iron, serum transferrin, total iron-binding capacity or proportion
of hypochromic red blood cells were measured every 8 weeks and at the
final visit.
Blood samples for assessment of study-drug immunogenicity were col-
lected at Weeks 1, 13, 27 and 40 and at the final visit. Physical examina-
tions were performed at baseline and at the final visit. Fractional clearance
of urea (Kt/V) or urea reduction ratio was used to assess adequacy of
haemodialysis at baseline. The use of any red blood cell transfusions, iron
supplementation and all concomitant treatments were recorded throughout
the study. The study ended in November 2008.
Statistical analyses
The study was powered to demonstrate an absolute difference of 15% in
the primary endpoint between the two groups. On the assumption that
60% of patients receiving methoxy polyethylene glycol-epoetin beta
and 45% of patients receiving darbepoetin alfa would fulfil the response
definition, a sample size of 244 patients per group would be adequate to
demonstrate a 15% higher response rate in the methoxy polyethylene
glycol-epoetin beta arm with 90% power and a significance level of 5%.
The two treatment arms were tested for a difference in the response
rate at the once-monthly dosing interval—the proportion of responders
in each group—using a two-sided Chi
2-test with Schouten correction
[10] at the 5% α-level.
The proportion of responders was analysed using frequency rates and
two-sided 95% confidence intervals based on the exact method of
Clopper and Pearson [11]. For the difference in proportions, the 95% con-
fidence interval with Hauck–Anderson correction [12] was calculated. In
addition, the risk ratio and the corresponding 95% confidence intervals
were determined.
Baseline haemoglobin was calculated by a time-adjusted mean of all
values recorded between the day of first study-drug administration and the
previous 30 days. The haemoglobin value on the day of the first dose was
included in the baseline calculation as this assessment was performed be-
fore the first dose was administered. A similar time-adjusted mean was
calculated using all haemoglobin values recorded in the evaluation period.
Subtracting the baseline value from the evaluation period value gave the
change in haemoglobin concentration between the baseline and evaluation
period. In the case of patients who entered the second treatment period
(once-monthly dosing schedule), missing haemoglobin values before
Week 53 were handled using the last-observation-carried-forward method.
To correct for any increase in haemoglobin caused by red blood cell trans-
fusions, the haemoglobin values measured within 3 weeks after a transfu-
sion were replaced by the haemoglobin value measured immediately
before the transfusion.
For the secondary efficacy endpoint, the percentage change between
the monthly dose at Week 27 and the average dose in months 11 and
12 was calculated in each treatment group. Five patients in the methoxy
polyethylene glycol-epoetin beta group and three patients in the darbepoe-
tin alfa group had a dose at Week 27 but not thereafter and were not in-
cluded in the analysis of dose change on the once-monthly dosing
schedule.
Descriptive safety analyses of adverse events, serious adverse events
and deaths were performed on all patients who received at least one dose
of study medication (safety follow-up population).
To ensure the safety of trial participants and the integrity of the trial, an
independent data and safety monitoring board (DSMB), consisting of two
clinical experts in nephrology and one statistician, monitored the trial for
evidence of beneficial or adverse effects. The DSMB was to review safety
results every 3 months. The DSMB could make recommendations for
continuation, modification or termination of the study. The trial is regis-
tered at www.ClinicalTrials.gov, number NCT00394953.
Results
Study population
A total of 490 patients were randomized from 82 centres in
13 countries. One patient assigned to the darbepoetin alfa
group did not receive any study medication and was ex-
cluded from the safety follow-up population (n=489).
Figure 1 shows that 335 patients completed the study
(187 given methoxy polyethylene glycol-epoetin beta and
148 given darbepoetin alfa), while 155 withdrew: 58 of
245 (24%) patients in the methoxy polyethylene glycol-
epoetin beta group and 97 of 245 (40%) patients in the dar-
bepoetin alfa group. Reasons for withdrawal were balanced
between groups and in each study period, with the excep-
tion of ‘insufficient therapeutic response’ as assessed by
the investigator, primarily in the once-monthly treatment
period [10 (4%) and 48 (20%) patients treated with meth-
oxy polyethylene glycol-epoetin beta and darbepoetin alfa,
respectively; P<0.0001].
Table 1 shows baseline characteristics for all rando-
mized patients, which were similar in the two treatment
groups and comparable to those in previously reported
studies of dialysis patients. Mean haemoglobin concentra-
Screening/
baseline period
Evaluation
(week 50–53)
R
Darbepoetin alfa
1x/week
Darbepoetin alfa
every 2 weeks
(n = 245)
Darbepoetin alfa
1x/month
4 weeks 26 weeks 26 weeks
Primary
endpoint
Methoxy polyethylene
glycol-epoetin beta
1x/month
(n = 245)
Methoxy polyethylene
glycol-epoetin beta
1x/month
Fig. 2. Treatment protocol. R = randomization.
4012 F. Carrera et al.tions at baseline, approximately 12.1 g/dL in both, did not
differ between groups. Both ferritin and transferrin satur-
ation were well within recommended limits; 85% (417 of
490) of patients received supplementary iron before
randomization.
During the study, a similar percentage of patients in
each group received concomitant iron treatment (91% in
the methoxy polyethylene glycol-epoetin beta group and
92% in the darbepoetin alfa group). The most common
supplements administered were intravenous iron sucrose
to 62% of patients in both groups and intravenous ferrous
gluconate to 24% of patients in the methoxy polyethylene
glycol-epoetin beta group and 23% in the darbepoetin alfa
group. Cumulative doses [median (interquartile range,
IQR)] of each of the preparations were roughly equal in
the two groups: iron sucrose 2100 mg (1325, 3200) and
1900 mg (1100, 2700); ferrous gluconate 2062 mg
(1406, 2937) and 2154 mg (1062, 2687) for methoxy
polyethylene glycol-epoetin beta and darbepoetin alfa,
respectively.
Angiotensin-converting enzyme inhibitors were admi-
nistered to 31% of patients and angiotensin II receptor an-
tagonists to 22% of patients in each group.
Thirty-nine patients (15.9%) in the methoxy polyethyl-
ene glycol-epoetin beta group and 32 (13.1%) in the dar-
bepoetin alfa group received at least one red blood cell
transfusion. The mean number of units of blood transfused
per patient was 1.56 and 1.64, respectively. Reasons given
for transfusions (in descending order of frequency) were
surgery, infection/inflammation, blood loss and anaemia
and were balanced between groups.
Efficacy
The response rate in the evaluation period was higher in
patients treated with methoxy polyethylene glycol-epoetin
beta than with darbepoetin alfa: 157 of 245 (64.1%) versus
99 of 245 (40.4%). The absolute difference of 23.7% (95%
CI 14.9–32.5) was statistically significant (P < 0.0001).
The relative risk of response with methoxy polyethylene
glycol-epoetin beta was 1.59 compared with darbepoetin
alfa (95% CI 1.33–1.90).
In the intent-to-treat population, the proportion of pa-
tients on the once-monthly treatment regimen who did
not fulfil the response criteria when treated with darbepoe-
tin alfa was more than double that in the methoxy poly-
ethylene glycol-epoetin beta group (50.2% versus 24.1%,
respectively; P < 0.0001).
As an additional exploratory assessment of treatment
effect at the once-monthly dosing interval, response was
calculated in a subset of patients who entered the second
treatment period: 157 of 216 (72.7%) versus 99 of 222
(44.6%) (P < 0.0001). The difference in response rates
was also found in an analysis of all patients who com-
pleted the study: 148 of 187 (79.1%) versus 91 of 148
(61.5%) (P < 0.0005).
The mean and median haemoglobin values for the two
treatment groups were close to 12 g/dL at baseline. During
the first treatment period, there was a parallel decline in the
median haemoglobin values in the two treatment groups,
with a nadir of the median haemoglobin at 11.1 g/dL at
Week 14 for methoxy polyethylene glycol-epoetin beta
and 11.2 g/dL for darbepoetin alfa at Week 16 (Figure 3).
Table 1. Baseline characteristics
Methoxy polyethylene glycol-epoetin beta
(n = 245)
Darbepoetin alfa
(n = 245)
Sex (male) 148 (60%) 156 (64%)
Age (years) 66.2 (13.6) 65.5 (13.9)
Race
Caucasian 233 (95%) 225 (92%)
Black 5 (2%) 12 (5%)
Oriental 5 (2%) 7 (3%)
Other 2 (<1%) 1 (<1%)
Weight (kg) 72.3 (15.1) 73.8 (16.9)
Haemoglobin (g/dL) 12.09 (0.56) 12.07 (0.55)
Ferritin (µg/L) 427 (276–614) 446 (282–663)
TSAT 26.5% (19.5–33.0) 26.6% (21.0–32.8)
Iron supplementation 208 (85%) 209 (85%)
Kt/V 1.54 (0.29) 1.52 (0.27)
Albumin (g/L) 38.9 (4.4) 39.2 (4.3)
Time since first dialysis (years) 4.20 (5.92) 4.15 (5.55)
Aetiology of kidney disease
Hypertension/large vessel disease 71 (29) 84 (34)
Diabetes 74 (30) 72 (29)
Glomerulonephritis 31 (13) 37 (15)
Interstitial nephritis/pyelonephritis 27 (11) 30 (12)
Polycystic kidney disease (adult type, dominant) 25 (10) 11 (4)
Previous median weekly darbepoetin alfa dose (µg) 30.0 20.0
Darbepoetin alfa dose per week before randomization
<40 µg 155 (63%) 164 (67%)
40–80 µg 80 (33%) 65 (27%)
>80 µg 10 (4%) 16 (7%)
Data are numbers (%), mean (SD) or median (IQR).
TSAT = transferrin saturation.
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0.5 g/dL from the nadir in both treatment arms until Week
26. During the 26 weeks of the second treatment period,
the haemoglobin curves diverged, with methoxy polyethyl-
ene glycol-epoetin beta remaining essentially unchanged,
while the median haemoglobinvalues with darbepoetin alfa
declined by 1.2 g/dL from baseline to the evaluation period.
The patients assigned to darbepoetin alfa once every
2 weeks were given double the dose administered in the
week before randomization (initial dose: mean 64.85 and
median 48.00 µg/2 weeks), while patients treated with
methoxy polyethylene glycol-epoetin beta received their
initial dose according to the conversion table (initial dose:
mean 159.38 and median 128.00 µg/month). Following
dose adjustments according to protocol in order to achieve
and maintain target (baseline) haemoglobin, doses were in-
creased in 50% of patients in both treatment groups. The
final doses in the first 26-week treatment period were:
mean 102.46 and median 75.00 µg/2 weeks for darbepoe-
tin alfa; mean 262.94 and median 200.00 µg/month for
methoxy polyethylene glycol-epoetin beta.
At Week 27, at the time of conversion to once-monthly
administration in the darbepoetin alfa treatment arm, the
mean (median) dose was 260.4 µg (200.0 µg) in the
methoxy polyethylene glycol-epoetin beta group and
202.8 µg (150.0 µg) in the darbepoetin alfa group
(Table 2). In months 11 and 12, the mean (median) doses
were 273.0 µg (196.0 µg) and 302.8 µg (225.0 µg) for
methoxy polyethylene glycol-epoetin beta and darbepoe-
tin alfa, respectively. The mean (median) dose change per
patient was 6.8% (0%) with methoxy polyethylene
glycol-epoetin beta and 58.8% (34.7%) with darbepoetin
alfa. In the second 26-week treatment period, more pa-
tients receiving darbepoetin alfa required a dose increase
to maintain target (baseline) Hb compared with those re-
ceiving methoxy polyethylene glycol-epoetin beta (58.4%
versus 31.8%, respectively), while fewer patients receiving
darbepoetin alfa required a dose decrease (4.6% versus
17.5%, respectively).
Adverse events
Of the 490 randomized patients, 489 received at least one
dose of study drug. In total, 90% (439 of 489) had at least
one adverse event, most of which were mild to moderate in
intensity (Table 3). The incidence of adverse events did not
differ between groups (P = 0.55). Six were judged to be re-
lated to treatment (four with methoxy polyethylene glycol-
epoetin beta and two with darbepoetin alfa, respectively).
Table 3 also shows the serious adverse events, which
were comparable in the two groups (P = 0.71). The most
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Methoxy polyethylene glycol-epoetin beta
Darbepoetin alfa
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glycol-epoetin beta 
Darbepoetin alfa
Evaluation
13
12
11
10
9
8
0
7
Baseline
Horizontal lines denote an Hb range of 11–13 g/dL
4 8 12 16 20 24 28 32 36 40 44 48
245 238 239 231 218 216 211 214 215 212 215 215 214
52
216
Weeks (of trial treatment)
M
e
d
i
a
n
 
h
a
e
m
o
g
l
o
b
i
n
 
l
e
v
e
l
 
(
g
/
d
L
)
245
n =
n = 237 239 234 232 234 218 219 220 218 217 218 218 222
Fig. 3. Median haemoglobin values over time with interquartile range (intent-to-treat population).
Table 2. Monthly dose of study drug
Methoxy polyethylene
glycol-epoetin beta
(n = 211)
Darbepoetin alfa
(n = 219)
Monthly dose in Week 27 (µg)
Mean (SD) 260.4 (193.8) 202.8 (183.5)
Median (IQR) 200.0 (120.0–313.0) 150.0 (80.0–280.0)
Monthly dose in Months 11 and 12 (µg)
Mean (SD) 273.0 (264.1) 302.8 (288.2)
Median (IQR) 196.0 (120.0–351.0) 225.0 (106.0–400.0)
Change in the monthly dose (%)
Mean (SD) 6.8 (51) 58.8 (76.5)
Median (IQR) 0.0 (-25.0–25.1) 34.7 (1.9–95.3)
4014 F. Carrera et al.common serious adverse events were arteriovenous fistula
site complication, arteriovenous fistula thrombosis and
sepsis. No patient had a serious adverse event that was
judged to be treatment related. Twenty-eight deaths (14
methoxy polyethylene glycol-epoetin beta patients and
14 darbepoetin alfa patients) occurred: 25 before the end
of the study and 3 after withdrawal and within 30 days of
last study-drug administration. When mortality was sum-
marized by patient exposure years, the death rates per
100 patient exposure years were 6.46 in the methoxy poly-
ethylene glycol-epoetin beta group and 6.57 in the darbe-
poetin alfa group. None of these 28 deaths were assessed
as study drug-related. Among the 28 deaths, 22 individual
causes were reported. The most common causes of death
were infections (seven cases), cardiac disorders (four
cases) and nervous system disorders (four cases). We noted
no clinically relevant changes in laboratory tests or vital
signs during the study. We did not detect antibodies to
study drugs.
Discussion
This study showed that treatment with methoxy polyethyl-
ene glycol-epoetin beta administered intravenously once
monthly was superior to treatment with darbepoetin alfa
administered intravenously at the same dosing interval
for the maintenance of haemoglobin concentrations in
haemodialysis patients. The proportion of all patients
who entered the study and met the response criteria of
no haemoglobin decrease from baseline exceeding 1 g/dL
and an average haemoglobin ≥10.5 g/dL during the final
evaluation period almost a year later was significantly
higher in patients treated with methoxy polyethylene gly-
col-epoetin beta than in those given darbepoetin alfa
(64.1% versus 40.4%; P < 0.0001). The median decline
in haemoglobin between baseline and the evaluation period
was 0.25 g/dL in the methoxy polyethylene glycol-epoetin
beta group and 1.09 g/dL in the darbepoetin alfa group,
despite the best efforts of investigators to maintain haemo-
globin by performing consecutive dose increases. It is like-
ly that the higher response rate with methoxy polyethylene
glycol-epoetin beta than with darbepoetin alfa can be ex-
plained primarily by the well-established difference in the
pharmacokinetics of the two drugs, specifically the longer
half-life of methoxy polyethylene glycol-epoetin beta, and
possibly by a difference between the two drugs in the re-
lationship between drug concentration and the pharmaco-
dynamic effect, i.e. the red blood cell production rate
[13,14].
A large majority of the patients completed the study, and
completion rates with methoxy polyethylene glycol-epoetin
beta were similar to those reported for other large studies
with methoxy polyethylene glycol-epoetin beta and other
erythropoiesis-stimulating agents administered at shorter
dosing intervals of similar duration [15–17]. There were
more premature withdrawals in the darbepoetin alfa group
(40%)thaninthemethoxypolyethyleneglycol-epoetinbeta
group (24%), and the difference was primarily attributable
to insufficient therapeutic response.
The secondary efficacy parameter was the change in
dose over time (difference between the monthly dose in
Week 27 and the average dose in months 11 and 12).
The virtually unchanged dose of methoxy polyethylene
glycol-epoetin beta corresponds to a stable haemoglobin
course with once-monthly dosing, while the dose increase
with darbepoetin alfa reflects the haemoglobin decline in a
large number of patients on the once-monthly regimen.
Extension of the administration intervals of erythropoi-
esis-stimulating agents to a once-monthly regimen has
been investigated in the interest of reducing the resources
required for anaemia management without compromising
haemoglobin control. Multiple studies with methoxy poly-
ethylene glycol-epoetin beta have demonstrated stable
haemoglobin values at the once-monthly dosing interval
[7,15,16]. There are also studies with traditional erythro-
poiesis-stimulating agents, several in patients with chronic
kidney disease not requiring dialysis [18–21] and one
study of patients on dialysis [22]. While the studies in
chronic kidney disease patients not on dialysis [18,20]
Table 3. Adverse events
Methoxy polyethylene glycol-epoetin
beta (n = 245) Darbepoetin alfa (n = 244)
Patients with AEs n (%) Events n Patients with AEs n (%) Events n
Hypertension* 36 (15%) 41 26 (11%) 29
Procedural hypotension* 21 (9%) 23 27 (11%) 39
Nasopharyngitis* 25 (10%) 32 20 (8%) 25
Muscle spasms* 21 (9%) 28 19 (8%) 23
Urinary tract infection* 23 (9%) 31 17 (7%) 19
Arteriovenous fistula site complication* 22 (9%) 29 17 (7%) 24
Diarrhoea* 18 (7%) 23 19 (8%) 20
Bronchitis* 20 (8%) 28 16 (7%) 19
Any adverse event 222 (91%) 1225 217 (89%) 1023
Serious adverse events 99 (40%) 167 94 (39%) 169
Adverse events leading to withdrawal 3 (1%) 7 (3%)
Deaths† 14 (6%) 14 (6%)
*Types of adverse events with incidence <7%.
†Twenty-five patients died before the end of the study and three after they had withdrawn from the study for other reasons.
Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa 4015used multiple epoetin alfa doses and dosing intervals in a
parallel-group study design with a treatment of 16 weeks,
the only study in dialysis patients [22] was an uncontrolled,
single-arm study in which administration intervals were
extended in patients defined as responders. Patients stable
on a once every 2 weeks darbepoetin alfa dosing regimen
were assigned to once every 3 weeks dosing, and only
those who maintained stable haemoglobin values accord-
ing to the protocol definition in the first 20-week period
were treated at the once every 4 weeks interval in the sub-
sequent 20 weeks. Moreover, if the haemoglobin concen-
tration was not within the target range, dosing could be
changed to a shorter interval; thus, in this study, increasing
the dosing interval out to once monthly was limited to ‘re-
sponder’ patients. In contrast, in the study reported here,
response at the once-monthly dosing interval was tested
in all patients randomized, allowing a direct comparison
of once-monthly methoxy polyethylene glycol-epoetin beta
and darbepoetin alfa.
The frequencies of adverse events and serious adverse
events were similar in the two treatment groups and charac-
teristic of the haemodialysis population. Adverse events
considered related to trial treatment by the investigator were
veryrareinbothtreatmentgroups(four patientsinthemeth-
oxy polyethylene glycol-epoetin beta group and two in the
darbepoetinalfagroup),whilstnoseriousadverseeventwas
assessed as related to the trial medication. Twenty-eight
deaths (14 methoxy polyethylene glycol-epoetin beta pa-
tients and 14 darbepoetin alfa patients) occurred during
the study, none reported as related to the study drug.
These results may be generalized to the maintenance
haemodialysis population. Patient characteristics at baseline,
includingtypicalcomorbidities,weresimilartothoseinother
clinical trials of intravenous erythropoiesis-stimulating
agents for maintenance of haemoglobin [15,23–25].
Limitations of our study include selection of patients
with stable haemoglobin at baseline and potential biases
in assessment of clinical endpoints, which are inherent to
all open-label clinical trials. However, haemoglobin con-
centration, the primary measure of efficacy, is objective
and not subject to bias. Since data on safety were collected
by many investigators in 82 different centres, systematic
skewing of the data is unlikely, and source data verification
confirmed that safety reporting was similarly complete for
both treatment groups.
In summary, treatment with methoxy polyethylene gly-
col-epoetin beta administered intravenously once monthly
was superior to treatment with darbepoetin alfa adminis-
tered intravenously at the same dosing interval for main-
taining haemoglobin concentrations in patients with
chronic kidney disease and renal anaemia (P < 0.0001)
despite dose increases with darbepoetin alfa. Safety find-
ings were characteristic of the population under study and
similar between the two treatment groups.
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Abstract
Background. Circulatingchemerin,anoveladipokinelinked
toobesity,glucosetoleranceandhyperlipidaemia,wasrecent-
ly reported to be increased in chronic kidney disease (CKD)
patients. We explored possible links between chemerin and
various clinical, nutritional and biochemical markers as well
as its association with 5-year all-cause mortality.
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